drugset / Trial / NCT00568815
Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and toxicity of Rituximab combined with ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) in the patients with diffuse large B cell lymphoma (DLBCL).
Timeline
- Start
- 2007-04
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Subject | Cytarabine | Small molecule | 2 g | — |
| Subject | Etoposide | Small molecule | 40 mg/m2 | — |
| Subject | Methylprednisolone | Other / unclassified | 500 mg/m2 | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |